Isn’t it time to consider oncological status as a new risk factor of iodinated contrast media hypersensitivity?

Show more: Authors information and Publication history
Authors Information

1Department of Pulmonology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
2Cliniques Universitaires Saint-Luc, Centre de l'allergie Saint-Luc, Brussels, Belgium
3Pole of Pulmonology, ENT and Dermatology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium


Published: 14 January 2022
Accepted: 05 January 2022
Received: 08 July 2021


Background. The literature describes several risk factors for hypersensitivity (HS) reactions to iodinated contrast media (ICM).Objective. To analyze the characteristics of patients experiencing HS reactions to ICM with a focus on oncological status. Methods. All patients (n = 80) with suspected HS to ICM who underwent an allergy evaluation in a Belgian University Hospital over a 5-year period were retrospectively included. Results. Overall, forty patients (50%) had a history of neoplasia, and this group was characterized by less atopy (p < 0.004). No significant difference was observed between oncological and non-oncological patients in terms of gender, age, cardiovascular diseases, medical treatment, and number of previous exposures or reactions to ICM. Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.

Iodinated contrast media; drug hypersensitivity; risk factors; cancer; targeted therapies.

Table of Content: Vol. 54 (No. 2) 2022 March

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024